Bolamin — EU research guide.
Bolamin is a Khavinson-series peptide bioregulator formulated for the bone marrow, proposed to support hematopoiesis and bone marrow stem cell function in aging models. It is one of the lesser-documented entries in the same research family as Thymalin and Vilon.
What is Bolamin?
Bolamin is a Khavinson-series peptide bioregulator formulated for the bone marrow, proposed to support hematopoiesis and bone marrow stem cell function in aging models. It is one of the lesser-documented entries in the same research family as Thymalin and Vilon.
What does the research show?
Published data is sparse even by the standards of this research family: no animal or human study under the name Bolamin was found in the sources checked. No independently replicated controlled trials are publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available only from a very small number of specialist research vendors.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Bolamin is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Group review of animal studies on peptide bioregulators. It mentions preparations from bone marrow among many tissues but gives no data specific to a product called Bolamin; all data come from the originating group. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Message 1: Results of experimental studies. Adv Gerontol. 2013;3(3):225-235. DOI
- Group review of clinical trials of seven peptide bioregulators. No bone marrow preparation is among them, so it provides no human evidence for this compound; it is also written by the developers. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Report 2: The results of clinical trials. Adv Gerontol. 2014;4(4):346-361. DOI